KIR2DL1 and acute lymphoblastic leukemia: At diagnosis of ALL, the percentage of NK showing CD158a expression was nonsignificantly higher; this parameter was the lowest in group II (after intense chemotherapy; P = 0.0001), and only slightly decreased after completing the treatment.